Clinical trial
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
NCT00372229 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00372229 |
|---|---|
| Title | A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation |
| Official title | A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Drug |
| Interventions | Valganciclovir CMV Prophylaxis, Valganciclovir (Pre-emptive CMV Therapy), Ganciclovir |
| Enrollment | 299 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2015 |
| Completion | Oct 1, 2015 |
| First posted | Sep 6, 2006 |
| Last update posted | Mar 11, 2020 |
| Countries | Austria, Germany |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: